The Quantellect read.As of Nov 19, 2026, 7 active firms cover Caribou Biosciences Inc: 3 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $1.00 to $11.00 (about 11.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.50 sits 1275% above the current $0.33. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 3 over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Neutral
Strong Buy00%
Buy343%
Neutral457%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.50
+1274.9% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.33 current
Highest Target$11.00
Average Target$4.50
Lowest Target$1.00
Detailed analyst forecasts for CRBU
Showing 1–5 of 5 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 3 of 7 active firms rate CRBU a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRBU EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Caribou Biosciences Inc to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-1.03, growing to $-0.65 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $25.7M, rising to $24.8M next year.
Top analysts covering Caribou Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRBU.
#1
Luca Issi
RBC Capital · Rank #76
Neutral
$1.00+205.5% to target
Overall win rate
49%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Neutral
No targeton CRBU
Overall win rate
42%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$8.00+2344.2% to target
Overall win rate
38%
+ Follow
#4
Daina Graybosch
Leerink Partners · Rank #396
Neutral
$1.00+205.5% to target
Overall win rate
41%
+ Follow
#5
Alec Stranahan
B of A Securities
Buy
$5.00+1427.7% to target
Coverage
—
+ Follow
CRBU stock forecast FAQ
What is CRBU's average 12-month price target?+
The 4 active firms with a live target average $4.50 for Caribou Biosciences Inc over the next 12 months, ranging from a $11.00 high to a $1.00 low, as of Nov 19, 2026.
Is CRBU stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 7 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRBU?+
The Street-high target is $11.00, and the Street-low is $1.00 (RBC Capital). The average of all 4 active-firm targets is $4.50.
How many active Wall Street firms cover CRBU?+
7 active firms have a recognized rating on Caribou Biosciences Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRBU?+
Among analysts who currently cover CRBU, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Neutral with a $1.00 target.
What is Caribou Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $-1.03, rising to $-0.65 the following year.
How much revenue is Caribou Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $25.7M, growing to $24.8M next year.
Have analysts been upgrading or downgrading CRBU lately?+
As of Nov 19, 2026, 3 of 7 active firms rate CRBU a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRBU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.